Cite
APA Citation
Xia, L., Peng, J., Lou, G., Pan, M., Zhou, Q., Hu, W., Shi, H., Wang, L., Gao, Y., Zhu, J., Zhang, Y., Sun, R., Zhou, X., Wang, Q., & Wu, X. (2022). antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open-label, multicenter phase 2 basket study. Journal for immunotherapy of cancer, 10(1), . http://access.bl.uk/ark:/81055/vdc_100148213479.0x000007